Free press releases distribution network?

Agency / Source: LifeSensors, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Abzyme Therapeutics Licenses SUMOpro from LifeSensors - Abzyme Therapeutics, LLC was founded to develop human therapeutic monoclonal antibodies. They have licensed LifeSensors protein expression platform, SUMOpro™ to further their monoclonal antibody production - LifeSensors.com
Abzyme Therapeutics Licenses SUMOpro from LifeSensors

 

PRZOOM - /newswire/ - Malvern, PA, United States, 2011/10/25 - Abzyme Therapeutics, LLC was founded to develop human therapeutic monoclonal antibodies. They have licensed LifeSensors protein expression platform, SUMOpro™ to further their monoclonal antibody production - LifeSensors.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Abzyme Therapeutics, a new biotechnology company dedicated to developing methods to generate human monoclonal antibodies for the treatment of disease, announced today that they have entered into an exclusive agreement with LifeSensors to license their proprietary protein expression platform, SUMOpro™. Enhanced protein expression is key to the evolution and development of antibodies and the LifeSensors SUMOpro™ technology is a protein expression platform that can dramatically enhance overall protein production through increased protein translation, solubility, and stability.

“The use of Abzyme Therapeutics’ systems and platforms will allow monoclonal antibodies to be used for the treatment of Alzheimer’s disease, cancer, autoimmune disease, and infectious diseases” said Dr. Tauseef Butt, co-founder and Chair of Abzyme Therapeutics Board of Directors.

Abzyme is currently focused on treating Alzheimer’s by developing proteolytic antibodies capable of hydrolyzing and clearing beta-amyloids from the human blood stream. These antibodies are designed to hydrolyze multiple antigen target molecules and overcome the problem of resistance, providing increased benefit at reduced doses. Alternatively, the generation irreversibly and repeatedly of these antibodies in the future will be critical in the development of treatments for cancers and other diseases.

Abzyme Therapeutics, LLC (abzymetx.com) has established its headquarters in the Great Valley Technology Center, Malvern, PA and aims to exploit their platforms for the development of novel therapeutic antibodies that will offer affordable medicines with increased benefit, requiring reduced dosages. With therapeutic antibody evolution platforms based on intracellular (iHUMab)/extracellular (eHuMab) genetic selection systems, Abzyme Therapeutics is capable of generating highly diversified human antibody repertoires.

LifeSensors, Inc. (lifesensors.com) is the leading producer of innovative research tools for the ubiquitin and ubiquitin-like protein pathways. Its prokaryotic and eukaryotic protein expression platforms SUMOpro™ and SUMOstar™ are used worldwide to overcome bottlenecks in protein production. LifeSensors’ technologies enable research once difficult to achieve by using a wide variety of high quality tools including enzymes, substrates, and inhibitors.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: LifeSensors, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Abzyme Therapeutics Licenses SUMOpro from LifeSensors

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Catherine Gorsky - LifeSensors.com 
610-644-8845 info[.]lifesensors.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any LifeSensors, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From LifeSensors, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Rapid Recovery

Visit  NAKIVO, Inc.







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today